E. Andreenko

发表

Ischemic Heart Disease in Subjects of Young Age: Current State of the Problem. Features of Etiology, Clinical Manifestation and Prognosis

I. S. Yavelov, S. Boytsov, O. Drapkina, 2018, Kardiologiia.

Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register)

S. Boytsov, O. Drapkina, S. Yakushin, 2019, Cardiovascular Therapy and Prevention.

The Therapy with Oral Anticoagulants in Patients with Atrial Fibrillation in Outpatient and Hospital Settings (Data from RECVASA Registries)

V. P. Mikhin, S. Boytsov, O. Drapkina, 2019, Rational Pharmacotherapy in Cardiology.

[Endothelial NO synthase and connexin 37 gene polymorphisms as a risk factor for myocardial infarction in subjects without a history of coronary artery disease].

V. Tkachuk, S. Boitsov, A. V. Balatskii, 2013, Terapevticheskii arkhiv.

Early cardiovascular multimorbidity in out- and in-patient care: age characteristics and medication therapy (data from the REKVAZA and REKVAZA-CLINIC registries)

A. A. Smirnov, S. Boytsov, O. Drapkina, 2020, Cardiovascular Therapy and Prevention.

Clinical and anamnestic characteristics and comorbidity in patients after myocardial infarction with and without arterial hypertension (data from the RECVASA-CLINIC registry)

O. Drapkina, E. V. Kudryashov, M. M. Lukyanov, 2019, Profilakticheskaya meditsina.

Combinations of NOS3 and CYBA alleles and essential hypertension risk in men

V. Tkachuk, E. Yarovaya, A. Balatsky, 2010 .

Patients with Atrial Fibrillation in Clinical Practice: Comorbidity, Drug Treatment and Outcomes (Data from RECVASA Registries)

V. P. Mikhin, S. Boytsov, O. Drapkina, 2020, Rational Pharmacotherapy in Cardiology.

Experience of creating and the first results of the prospective hospital registry of patients with suspected or confirmed coronavirus infection (COVID-19) and community-acquired pneumonia (TARGET-VIP)

A. A. Smirnov, O. Drapkina, A. Pulin, 2020 .

Detection rate and characteristics of heart failure, depending on the diagnostic criteria in COVID-19 survivors one year after hospitalization

A. A. Smirnov, A. Pulin, S. Martsevich, 2023, Cardiovascular Therapy and Prevention.

Evaluation of microRNA‑486‑3p Molecular Signature in Patients with Autism Spectrum Disorder

I. Minkov, N. Popov, V. Stoyanova, 2021 .

Long-term outcomes in patients after COVID-19: data from the TARGET-VIP registry

A. A. Smirnov, O. Drapkina, A. Pulin, 2022, Russian Journal of Cardiology.

Prehospital Period in Patients with COVID-19: Cardiovascular Comorbidity and Pharmacotherapy During the First Epidemic Wave (Hospital Registry Data)

A. A. Smirnov, O. Drapkina, S. Martsevich, 2022, Rational Pharmacotherapy in Cardiology.

Clinical and Anamnestic Characteristics, Cardiovascular Pharmacotherapy and Long-term Outcomes in Multimorbid Patients after COVID-19

A. A. Smirnov, A. Pulin, S. Martsevich, 2022, Rational Pharmacotherapy in Cardiology.

Outpatient register of patients who have suffered a myocardial infarction (REGATA): prospective follow-up data and outcomes.

S. Yakushin, K. Pereverzeva, E. Pravkina, 2022, Kardiologiia.

Patients with a Combination of Atrial Fibrillation and Chronic Heart Failure in Clinical Practice: Comorbidities, Drug Treatment and Outcomes

V. P. Mikhin, S. Boytsov, O. Drapkina, 2022, Rational Pharmacotherapy in Cardiology.

PATIENTS WITH COMBINATION OF CHRONIC HEART FAILURE, HYPERTENSION AND HISTORY OF MYOCARDIAL INFARCTION: CLINICAL AND ANAMNESTIC CHARACTERISTICS, ADMINISTRATION OF ACE INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, -BLOCKERS AND ADHERENCE TO THE DRUG THERAPY (DATA OF OUTPATIENT REGISTRY RECVASA)

A. Deev, S. Boytsov, S. Martsevich, 2017 .

Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines

Y. Balanova, O. Drapkina, S. Yakushin, 2024, Cardiovascular Therapy and Prevention.